Literature DB >> 24936056

The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.

Lei Duan1, Guoguang Ying2, Brian Danzer3, Ricardo E Perez3, Zia Shariat-Madar4, Victor V Levenson5, Carl G Maki6.   

Abstract

The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT)/mammalian target of rapamycin (mTOR) pathway conveys signals from receptor tyrosine kinases (RTKs) to regulate cell metabolism, proliferation, survival, and motility. Previously we found that prolylcarboxypeptidase (PRCP) regulate proliferation and survival in breast cancer cells. In this study, we found that PRCP and the related family member prolylendopeptidase (PREP) are essential for proliferation and survival of pancreatic cancer cells. Depletion/inhibition of PRCP and PREP-induced serine phosphorylation and degradation of IRS-1, leading to inactivation of the cellular PI3K and AKT. Notably, depletion/inhibition of PRCP/PREP destabilized IRS-1 in the cells treated with rapamycin, blocking the feedback activation PI3K/AKT. Consequently, inhibition of PRCP/PREP enhanced rapamycin-induced cytotoxicity. Thus, we have identified PRCP and PREP as a stabilizer of IRS-1 which is critical for PI3K/AKT/mTOR signaling in pancreatic cancer cells.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Akt PKB; Apoptosis; Cancer Therapy; Cell Death; Cell Signaling; Mammalian Target of Rapamycin (mTOR); Phosphatidylinositide 3-Kinase (PI 3-kinase)

Mesh:

Substances:

Year:  2014        PMID: 24936056      PMCID: PMC4118128          DOI: 10.1074/jbc.M114.550038

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

3.  Mechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin II.

Authors:  Yoshihiro Taniyama; Hirofumi Hitomi; Anand Shah; R Wayne Alexander; Kathy K Griendling
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-03-31       Impact factor: 8.311

4.  Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation.

Authors:  T M Pederson; D L Kramer; C M Rondinone
Journal:  Diabetes       Date:  2001-01       Impact factor: 9.461

5.  Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma.

Authors:  Shinji Yamamoto; Yasuhiko Tomita; Yoshihiko Hoshida; Takaya Morooka; Hiroaki Nagano; Keizo Dono; Koji Umeshita; Masato Sakon; Osamu Ishikawa; Hiroaki Ohigashi; Shoji Nakamori; Morito Monden; Katsuyuki Aozasa
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

6.  Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers.

Authors:  Y R Hadari; E Tzahar; O Nadiv; P Rothenberg; C T Roberts; D LeRoith; Y Yarden; Y Zick
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

7.  Recombinant prolylcarboxypeptidase activates plasma prekallikrein.

Authors:  Zia Shariat-Madar; Fakhri Mahdi; Alvin H Schmaier
Journal:  Blood       Date:  2004-03-02       Impact factor: 22.113

Review 8.  Proline motifs in peptides and their biological processing.

Authors:  G Vanhoof; F Goossens; I De Meester; D Hendriks; S Scharpé
Journal:  FASEB J       Date:  1995-06       Impact factor: 5.191

9.  Increased expression of insulin receptor substrate-1 in human pancreatic cancer.

Authors:  U Bergmann; H Funatomi; M Kornmann; H G Beger; M Korc
Journal:  Biochem Biophys Res Commun       Date:  1996-03-27       Impact factor: 3.575

10.  Incidence, mechanism and prognostic value of activated AKT in pancreas cancer.

Authors:  M G Schlieman; B N Fahy; R Ramsamooj; L Beckett; R J Bold
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640

View more
  6 in total

1.  Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.

Authors:  Ricardo E Perez; Sarah Calhoun; Daeun Shim; Victor V Levenson; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

2.  Ubiquitinated CD36 sustains insulin-stimulated Akt activation by stabilizing insulin receptor substrate 1 in myotubes.

Authors:  Shishuo Sun; Pengcheng Tan; Xiaoheng Huang; Wei Zhang; Chen Kong; Fangfang Ren; Xiong Su
Journal:  J Biol Chem       Date:  2017-12-21       Impact factor: 5.157

3.  The MSDIN family in amanitin-producing mushrooms and evolution of the prolyl oligopeptidase genes.

Authors:  Hong Luo; Qing Cai; Yunjiao Lüli; Xuan Li; Rohita Sinha; Heather E Hallen-Adams; Zhu L Yang
Journal:  IMA Fungus       Date:  2018-08-01       Impact factor: 3.515

4.  Jowiseungki decoction affects diabetic nephropathy in mice through renal injury inhibition as evidenced by network pharmacology and gut microbiota analyses.

Authors:  Xianglong Meng; Junnan Ma; Seok Yong Kang; Hyo Won Jung; Yong-Ki Park
Journal:  Chin Med       Date:  2020-03-12       Impact factor: 5.455

5.  Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer.

Authors:  Lei Duan; Sarah Calhoun; Ricardo E Perez; Virgilia Macias; Fatima Mir; Melissa R Pergande; Paolo Gattuso; Jeffrey A Borgia; Carl G Maki
Journal:  Cancers (Basel)       Date:  2022-01-31       Impact factor: 6.575

6.  Identification of protein kinase inhibitors to reprogram breast cancer cells.

Authors:  Jie Yuan; Fan Zhang; Meng You; Qin Yang
Journal:  Cell Death Dis       Date:  2018-09-11       Impact factor: 9.685

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.